21
Jan
2020

SHOP APOTHEKE EUROPE continues to grow dynamically; 2019 revenues increase to over EUR 700 million.



DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Preliminary Results/Development of Sales
21.01.2020 / 07:00
The issuer is solely responsible for the content of this announcement.

SHOP APOTHEKE EUROPE continues to grow dynamically; 2019 revenues increase to over EUR 700 million.


Venlo/Cologne, 21 January 2020. Based on preliminary and unaudited results, SHOP APOTHEKE EUROPE N.V. has clearly met its forecast for the just-ended fiscal year (balance sheet date: 31 December). The online pharmacy again grew dynamically, at a rate of c. 30%, during the 2019 financial year. Preliminary calculations show revenues of around EUR 701 million (2018: EUR 539.7 million) for the 2019 fiscal year with the adjusted EBITDA margin in the projected range of -2.0% to -2.3%. During the fourth quarter 2019, the online pharmacy increased its consolidated revenues to c. EUR 192 million after 151 during the same period a year earlier.

The dynamic revenue growth is due to the rise in the number of active customers in Europa from 3.5 million at the end of 2018 to around 4.7 million at the end of 2019. That means the increase in revenues is almost entirely the result of organic growth (28%).

The sale of prescription drugs (Rx) increased by about 11% year-on-year. "We just had a new record of receiving over 7,000 prescriptions on a single day", says SHOP APOTHEKE EUROPE CEO Stefan Feltens. "We are expecting another substantial increase in our prescription drugs business following the nationwide launch of electronic prescriptions in Germany, which we expect to happen in 2021. Customers will then be able to benefit from all the advantages of online buying."

SHOP APOTHEKE EUROPE will publish its detailed 2019 financial results in its consolidated financial statement for the 2019 fiscal year on 17 March 2020.
 

ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is one of the leading and the fastest-growing online pharmacies in Continental Europe. With the acquisition of Europa Apotheek Venlo in November 2017, SHOP APOTHEKE EUROPE significantly extended its European market leadership. The product range for the whole family in the OTC, beauty and personal care products as well as prescription drugs segments is supplemented by high quality natural food and health products, low carb products and sports nutrition following the acquisition of nu3 GmbH in July 2018.

SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to over 4.7 million active customers fast and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive pharmaceutical consulting services.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016 and is part of the SDAX index since 24 September 2018.

In addition to being traded on the Frankfurt stock exchange, since June 25, 2019, SHOP APOTHEKE EUROPE's convertible bonds (ISIN: DE000A19Y072), are also tradeable on the Dutch Euronext stock exchange, which operates the stock exchanges in Paris, Amsterdam, Brussels and Lisbon.

 

MEDIA CONTACTS.

Trade and popular media:
Sven Schirmer
Tel: +49 221 99 53 44 31
Email: presse@shop-apotheke.com

Financial media:
Thomas Schnorrenberg
Mobile: +49 151 465 31317

Bettina Fries
Tel: +49 211 75 80 779

Email: presse@shop-apotheke.com

Investor relations:
Carmen Herkenrath
Tel.: +31 77 850 6109
Email: carmen.herkenrath@shop-apotheke.com

 

 



21.01.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this